~18 spots leftby Apr 2026

Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery

Recruiting in Palo Alto (17 mi)
GS
Overseen byGlenn S Murphy, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Recruiting
Sponsor: Endeavor Health
Prior Safety Data

Trial Summary

What is the purpose of this trial?

A number of drugs used in the perioperative period may cause prolongation of the QT interval on the electrocardiogram (EKG). These drugs include inhalational agents, antiemetic agents, pain medications, and drugs used to reverse the effects of muscle relaxants. Approximately 80% of patients undergoing a general anesthetic will demonstrate significant prolongation of the QT interval on the EKG in the postanesthesia care unit (PACU) following surgery. The concern with QT interval prolongation is that it can result in a potentially lethal ventricular arrhythmia termed torsade des pointes. Despite the concurrent use of several of these medications in a typical general anesthetic, torsade des pointes is a rare event in the perioperative period. In the past decade, the use of intravenous methadone as part of a balanced anesthetic technique has increased significantly. A single dose provided at induction of anesthesia can provide prolonged (24-48 hours) relief from pain. Studies in patients receiving long-term treatment with methadone for addiction therapy or chronic pain have revealed that these patients are at risk for QT prolongation, torsade des pointe, and cardiac death. However, the effect of a single intravenous dose of methadone used in the operating room on the QT interval is uncertain. The aim of this randomized clinical trial is to compare the impact of methadone, when compared to the more commonly-used opioid hydromorphone, on QT prolongation measured with a 12-lead EKG in the PACU and on postoperative day 1. We hypothesize that methadone will not result in significant QT prolongation when used as part of a standardized general anesthetic.

Research Team

GS

Glenn S Murphy, MD

Principal Investigator

Endeavor Health

Eligibility Criteria

Inclusion Criteria

All patients presenting for elective surgical cases requiring general anesthesia and associated with moderate-to-severe postoperative pain will be eligible for enrollment.

Treatment Details

Interventions

  • Hydromorphone (Opioid)
  • Methadone (Opioid)
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: methadone groupActive Control1 Intervention
Patients in this group will receive a syringe of methadone at the induction of anesthesia and a syringe of saline at the end of anesthesia.
Group II: hydromorphone groupPlacebo Group1 Intervention
Patients in this group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia

Hydromorphone is already approved in United States, Canada, European Union for the following indications:

πŸ‡ΊπŸ‡Έ Approved in United States as Dilaudid for:
  • Moderate to severe pain
πŸ‡¨πŸ‡¦ Approved in Canada as Hydromorphone for:
  • Moderate to severe pain
πŸ‡ͺπŸ‡Ί Approved in European Union as Hydromorphone for:
  • Moderate to severe pain

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
NorthShore University HealthSystemEvanston, IL
Loading ...

Who Is Running the Clinical Trial?

Endeavor Health

Lead Sponsor

Trials
135
Patients Recruited
742,000+

NorthShore University HealthSystem

Lead Sponsor

Trials
134
Patients Recruited
740,000+